Korea Investment CORP grew its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 6.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 39,289 shares ...

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Its products include treatments for pulmonary arterial hypertension (PAH), such as Tyvaso, Remodulin, and Orenitram, as well as a monoclonal antibody for high-risk neuroblastoma called Unituxin.

After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon.

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.